A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma.

Trial Profile

A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2012

At a glance

  • Drugs Ficlatuzumab (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Biomarker; Registrational
  • Most Recent Events

    • 01 Feb 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 07 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top